Omeros
About Omeros PipelineInvestorsNews

Press Releases

Date Title  
04/03/19 Omeros Corporation Announces EBMT Case Report of Resolution of Gastrointestinal Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Following Narsoplimab Treatment
-- Growing Identification of HSCT-TMA a Focus of Recent Annual Meeting of the European Society for Blood and Marrow Transplantation -- SEATTLE --(BUSINESS WIRE)--Apr. 3, 2019-- Omeros Corporation  (Nasdaq: OMER) today announced the recent presentation of a case report describing resolution of
03/19/19 Omeros Corporation Announces Upcoming Educational Event at the Annual Meeting of the European Society of Blood and Marrow Transplantation
--Session Will Focus on Diagnosis of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy-- SEATTLE --(BUSINESS WIRE)--Mar. 19, 2019-- Omeros Corporation  (Nasdaq: OMER) today announced an upcoming educational event at the 2019 Annual Meeting of the European Society of Blood and
03/01/19 Omeros Corporation Reports Fourth Quarter and Year-End 2018 Financial Results
– Conference Call Today at 8:30 a.m. ET – SEATTLE --(BUSINESS WIRE)--Mar. 1, 2019-- Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan
02/26/19 Omeros Corporation to Announce Fourth Quarter and Year-End 2018 Financial Results on March 1, 2019
SEATTLE --(BUSINESS WIRE)--Feb. 26, 2019-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end 2018 financial results for the period ended December 31, 2018 , on Friday, March 1, 2019 , before the market opens.
02/20/19 Omeros Corporation Announces USAN and INN Selection of Nonproprietary Name for OMS721
SEATTLE --(BUSINESS WIRE)--Feb. 20, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that, as the company prepares for planned commercialization of OMS721, the United States Adopted Names (USAN) Council , in consultation with the World Health Organization’s International Nonproprietary
02/14/19 Omeros Corporation Streamlines Path to Biologics License Application for OMS721 in HSCT-TMA Following Meeting with FDA
Patient Data from Existing Single-Arm Study Will Form the Basis for BLA; No Historical Control Required SEATTLE --(BUSINESS WIRE)--Feb. 14, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that, based on a recent meeting with the U.S. Food and Drug Administration ( FDA ), the company has
02/12/19 Omeros Corporation Appoints Thomas F. Bumol, Ph.D., to Board of Directors
-- Former Lilly Biotechnology and Immunology Senior Vice President Drawn by Omeros’ Complement Franchise and Novel-Product Pipeline -- SEATTLE --(BUSINESS WIRE)--Feb. 12, 2019-- Omeros Corporation (NASDAQ: OMER) today announced the appointment of Thomas F. Bumol , Ph.D., to its Board of Directors.
01/17/19 Omeros Finalizes with FDA Clinical Plan for OMS721 Approval in IgA Nephropathy
--Additional Positive Data Reported from Second Cohort in Phase 2 Trial-- SEATTLE --(BUSINESS WIRE)--Jan. 17, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that it has finalized its clinical plan for OMS721 submission and approval in immunoglobulin A nephropathy (IgAN) following a recent
01/14/19 Omeros Corporation Announces Record High Quarterly Revenue Results for the Fourth Quarter 2018
– Broadening OMIDRIA Coverage from Payers and Increasing Funding for OMS721 Commercial Preparations – SEATTLE --(BUSINESS WIRE)--Jan. 14, 2019-- Omeros Corporation (Nasdaq: OMER), today announced unaudited preliminary revenue results for the fourth quarter ended December 31, 2018 .